Compare XEL & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XEL | ONC |
|---|---|---|
| Founded | 1909 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.5B | 34.8B |
| IPO Year | N/A | N/A |
| Metric | XEL | ONC |
|---|---|---|
| Price | $76.51 | $342.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | $83.79 | ★ $369.50 |
| AVG Volume (30 Days) | ★ 5.6M | 294.7K |
| Earning Date | 02-05-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.27 | 0.58 |
| Revenue | ★ $14,228,000,000.00 | $4,972,687,000.00 |
| Revenue This Year | $13.06 | $895.40 |
| Revenue Next Year | $7.62 | $22.04 |
| P/E Ratio | ★ $23.33 | $571.70 |
| Revenue Growth | 3.38 | ★ 50.43 |
| 52 Week Low | $65.21 | $196.45 |
| 52 Week High | $83.01 | $385.22 |
| Indicator | XEL | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 57.38 | 58.08 |
| Support Level | $74.67 | $325.10 |
| Resistance Level | $76.39 | $353.10 |
| Average True Range (ATR) | 1.34 | 10.87 |
| MACD | 0.45 | 2.39 |
| Stochastic Oscillator | 87.35 | 78.76 |
Xcel Energy manages utilities serving 3.8 million electric customers and 2.2 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan; Public Service Company of Colorado; and Southwestern Public Service Company, which serves customers in Texas and New Mexico. It is one of the largest renewable energy suppliers in the US, with more than half of its electricity sales coming from carbon-free energy.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.